Niagen Bioscience (NAGE) Total Current Liabilities (2011 - 2026)

Niagen Bioscience (NAGE) has 14 years of Total Current Liabilities data on file, last reported at $22.8 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $22.8 million, up 9.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $22.8 million (up 9.54% YoY), and the FY2025 annual result was $19.9 million, up 10.98% from the prior year.
• Total Current Liabilities advanced to $22.8 million in Q1 2026 per NAGE's latest filing, from $19.9 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $22.8 million in Q1 2026 and troughed at $16.7 million in Q3 2022.
• A 5-year average of $19.4 million and a median of $19.1 million in 2023 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities decreased 12.97% in 2024, then climbed 28.32% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $17.9 million in 2022, then grew by 15.41% to $20.6 million in 2023, then decreased by 12.97% to $17.9 million in 2024, then climbed by 10.98% to $19.9 million in 2025, then climbed by 14.58% to $22.8 million in 2026.
• Business Quant data shows NAGE's Total Current Liabilities at $22.8 million in Q1 2026, $19.9 million in Q4 2025, and $22.7 million in Q3 2025.